The global market for Novel Vaccine Delivery Systems was estimated to be worth US$ 7163 million in 2024 and is forecast to a readjusted size of US$ 14540 million by 2031 with a CAGR of 10.8% during the forecast period 2025-2031.
Novel vaccine delivery includes formulations, technologies, methods, and systems to transfer an active pharmaceutical ingredient in the body, as desired, in order to safely accomplish its therapeutic effect.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Novel Vaccine Delivery Systems, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Novel Vaccine Delivery Systems by region & country, by Type, and by Application.
The Novel Vaccine Delivery Systems market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Vaccine Delivery Systems.
Global Novel Vaccine Delivery Systems Companies Covered
Altaris Capital Partners, Kindeva Drug Delivery, Becton, Dickinson,, Carl Zeiss Foundation, Gerresheimer AG, Corium International, Inovio Pharmaceuticals, Bioject Medical Technologies, PharmaJet, Retractable Technologies, Terumo Corporation, VAXXAS
Global Novel Vaccine Delivery Systems Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Novel Vaccine Delivery Systems Market, Segment by Type
Intradermal Delivery
Intramuscular Delivery
Others
Global Novel Vaccine Delivery Systems Market, Segment by Application
Hospitals & Clinics
Research Institutes
Others
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Novel Vaccine Delivery Systems company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Novel Vaccine Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Novel Vaccine Delivery Systems in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Related Reports:
Global Nanotechnology-based Drug Delivery Systems Market Size, Share, Key Players, Competitive Landscape, Growth Drivers, Trends, Opportunities, Revenue Analysis, and Demand Forecast to 2032
Global Chemical Delivery Systems Market Size, Share, Growth Drivers, Trends, Opportunities, Competitive Analysis, and Forecast To 2030
Table of Contents
1 Market Overview
1.1 Novel Vaccine Delivery Systems Product Introduction
1.2 Global Novel Vaccine Delivery Systems Market Size Forecast (2020-2031)
1.3 Novel Vaccine Delivery Systems Market Trends & Drivers
1.3.1 Novel Vaccine Delivery Systems Industry Trends
1.3.2 Novel Vaccine Delivery Systems Market Drivers & Opportunity
1.3.3 Novel Vaccine Delivery Systems Market Challenges
1.3.4 Novel Vaccine Delivery Systems Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Novel Vaccine Delivery Systems Players Revenue Ranking (2024)
2.2 Global Novel Vaccine Delivery Systems Revenue by Company (2020-2025)
2.3 Key Companies Novel Vaccine Delivery Systems Manufacturing Base Distribution and Headquarters
2.4 Key Companies Novel Vaccine Delivery Systems Product Offered
2.5 Key Companies Time to Begin Mass Production of Novel Vaccine Delivery Systems
2.6 Novel Vaccine Delivery Systems Market Competitive Analysis
2.6.1 Novel Vaccine Delivery Systems Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Novel Vaccine Delivery Systems Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Vaccine Delivery Systems as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Intradermal Delivery
3.1.2 Intramuscular Delivery
3.1.3 Others
3.2 Global Novel Vaccine Delivery Systems Sales Value by Type
3.2.1 Global Novel Vaccine Delivery Systems Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Type (2020-2031)
3.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals & Clinics
4.1.2 Research Institutes
4.1.3 Others
4.2 Global Novel Vaccine Delivery Systems Sales Value by Application
4.2.1 Global Novel Vaccine Delivery Systems Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Novel Vaccine Delivery Systems Sales Value, by Application (2020-2031)
4.2.3 Global Novel Vaccine Delivery Systems Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Novel Vaccine Delivery Systems Sales Value by Region
5.1.1 Global Novel Vaccine Delivery Systems Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025)
5.1.3 Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031)
5.1.4 Global Novel Vaccine Delivery Systems Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Novel Vaccine Delivery Systems Sales Value, 2020-2031
5.2.2 North America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Novel Vaccine Delivery Systems Sales Value, 2020-2031
5.3.2 Europe Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Novel Vaccine Delivery Systems Sales Value, 2020-2031
5.4.2 Asia Pacific Novel Vaccine Delivery Systems Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Novel Vaccine Delivery Systems Sales Value, 2020-2031
5.5.2 South America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Novel Vaccine Delivery Systems Sales Value, 2020-2031
5.6.2 Middle East & Africa Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.3 United States
6.3.1 United States Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.3.2 United States Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.4.2 Europe Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.5.2 China Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.5.3 China Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.6.2 Japan Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.7.2 South Korea Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.8.2 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Novel Vaccine Delivery Systems Sales Value, 2020-2031
6.9.2 India Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
6.9.3 India Novel Vaccine Delivery Systems Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Altaris Capital Partners
7.1.1 Altaris Capital Partners Profile
7.1.2 Altaris Capital Partners Main Business
7.1.3 Altaris Capital Partners Novel Vaccine Delivery Systems Products, Services and Solutions
7.1.4 Altaris Capital Partners Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.1.5 Altaris Capital Partners Recent Developments
7.2 Kindeva Drug Delivery
7.2.1 Kindeva Drug Delivery Profile
7.2.2 Kindeva Drug Delivery Main Business
7.2.3 Kindeva Drug Delivery Novel Vaccine Delivery Systems Products, Services and Solutions
7.2.4 Kindeva Drug Delivery Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.2.5 Kindeva Drug Delivery Recent Developments
7.3 Becton
7.3.1 Becton Profile
7.3.2 Becton Main Business
7.3.3 Becton Novel Vaccine Delivery Systems Products, Services and Solutions
7.3.4 Becton Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.3.5 Becton Recent Developments
7.4 Dickinson,
7.4.1 Dickinson, Profile
7.4.2 Dickinson, Main Business
7.4.3 Dickinson, Novel Vaccine Delivery Systems Products, Services and Solutions
7.4.4 Dickinson, Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.4.5 Dickinson, Recent Developments
7.5 Carl Zeiss Foundation
7.5.1 Carl Zeiss Foundation Profile
7.5.2 Carl Zeiss Foundation Main Business
7.5.3 Carl Zeiss Foundation Novel Vaccine Delivery Systems Products, Services and Solutions
7.5.4 Carl Zeiss Foundation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.5.5 Carl Zeiss Foundation Recent Developments
7.6 Gerresheimer AG
7.6.1 Gerresheimer AG Profile
7.6.2 Gerresheimer AG Main Business
7.6.3 Gerresheimer AG Novel Vaccine Delivery Systems Products, Services and Solutions
7.6.4 Gerresheimer AG Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.6.5 Gerresheimer AG Recent Developments
7.7 Corium International
7.7.1 Corium International Profile
7.7.2 Corium International Main Business
7.7.3 Corium International Novel Vaccine Delivery Systems Products, Services and Solutions
7.7.4 Corium International Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.7.5 Corium International Recent Developments
7.8 Inovio Pharmaceuticals
7.8.1 Inovio Pharmaceuticals Profile
7.8.2 Inovio Pharmaceuticals Main Business
7.8.3 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Products, Services and Solutions
7.8.4 Inovio Pharmaceuticals Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.8.5 Inovio Pharmaceuticals Recent Developments
7.9 Bioject Medical Technologies
7.9.1 Bioject Medical Technologies Profile
7.9.2 Bioject Medical Technologies Main Business
7.9.3 Bioject Medical Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
7.9.4 Bioject Medical Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.9.5 Bioject Medical Technologies Recent Developments
7.10 PharmaJet
7.10.1 PharmaJet Profile
7.10.2 PharmaJet Main Business
7.10.3 PharmaJet Novel Vaccine Delivery Systems Products, Services and Solutions
7.10.4 PharmaJet Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.10.5 PharmaJet Recent Developments
7.11 Retractable Technologies
7.11.1 Retractable Technologies Profile
7.11.2 Retractable Technologies Main Business
7.11.3 Retractable Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
7.11.4 Retractable Technologies Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.11.5 Retractable Technologies Recent Developments
7.12 Terumo Corporation
7.12.1 Terumo Corporation Profile
7.12.2 Terumo Corporation Main Business
7.12.3 Terumo Corporation Novel Vaccine Delivery Systems Products, Services and Solutions
7.12.4 Terumo Corporation Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.12.5 Terumo Corporation Recent Developments
7.13 VAXXAS
7.13.1 VAXXAS Profile
7.13.2 VAXXAS Main Business
7.13.3 VAXXAS Novel Vaccine Delivery Systems Products, Services and Solutions
7.13.4 VAXXAS Novel Vaccine Delivery Systems Revenue (US$ Million) & (2020-2025)
7.13.5 VAXXAS Recent Developments
8 Industry Chain Analysis
8.1 Novel Vaccine Delivery Systems Industrial Chain
8.2 Novel Vaccine Delivery Systems Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Novel Vaccine Delivery Systems Sales Model
8.5.2 Sales Channel
8.5.3 Novel Vaccine Delivery Systems Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. Novel Vaccine Delivery Systems Market Trends
Table 2. Novel Vaccine Delivery Systems Market Drivers & Opportunity
Table 3. Novel Vaccine Delivery Systems Market Challenges
Table 4. Novel Vaccine Delivery Systems Market Restraints
Table 5. Global Novel Vaccine Delivery Systems Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Novel Vaccine Delivery Systems Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Novel Vaccine Delivery Systems Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Novel Vaccine Delivery Systems Product Type
Table 9. Key Companies Time to Begin Mass Production of Novel Vaccine Delivery Systems
Table 10. Global Novel Vaccine Delivery Systems Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Vaccine Delivery Systems as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Novel Vaccine Delivery Systems Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Novel Vaccine Delivery Systems Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Novel Vaccine Delivery Systems Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Type (2020-2025)
Table 17. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Type (2026-2031)
Table 18. Global Novel Vaccine Delivery Systems Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Novel Vaccine Delivery Systems Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Novel Vaccine Delivery Systems Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Application (2020-2025)
Table 22. Global Novel Vaccine Delivery Systems Sales Market Share in Value by Application (2026-2031)
Table 23. Global Novel Vaccine Delivery Systems Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Novel Vaccine Delivery Systems Sales Value by Region (2020-2025) & (%)
Table 27. Global Novel Vaccine Delivery Systems Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value, (2026-2031) & (US$ Million)
Table 31. Altaris Capital Partners Basic Information List
Table 32. Altaris Capital Partners Description and Business Overview
Table 33. Altaris Capital Partners Novel Vaccine Delivery Systems Products, Services and Solutions
Table 34. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Altaris Capital Partners (2020-2025)
Table 35. Altaris Capital Partners Recent Developments
Table 36. Kindeva Drug Delivery Basic Information List
Table 37. Kindeva Drug Delivery Description and Business Overview
Table 38. Kindeva Drug Delivery Novel Vaccine Delivery Systems Products, Services and Solutions
Table 39. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Kindeva Drug Delivery (2020-2025)
Table 40. Kindeva Drug Delivery Recent Developments
Table 41. Becton Basic Information List
Table 42. Becton Description and Business Overview
Table 43. Becton Novel Vaccine Delivery Systems Products, Services and Solutions
Table 44. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Becton (2020-2025)
Table 45. Becton Recent Developments
Table 46. Dickinson, Basic Information List
Table 47. Dickinson, Description and Business Overview
Table 48. Dickinson, Novel Vaccine Delivery Systems Products, Services and Solutions
Table 49. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Dickinson, (2020-2025)
Table 50. Dickinson, Recent Developments
Table 51. Carl Zeiss Foundation Basic Information List
Table 52. Carl Zeiss Foundation Description and Business Overview
Table 53. Carl Zeiss Foundation Novel Vaccine Delivery Systems Products, Services and Solutions
Table 54. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Carl Zeiss Foundation (2020-2025)
Table 55. Carl Zeiss Foundation Recent Developments
Table 56. Gerresheimer AG Basic Information List
Table 57. Gerresheimer AG Description and Business Overview
Table 58. Gerresheimer AG Novel Vaccine Delivery Systems Products, Services and Solutions
Table 59. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Gerresheimer AG (2020-2025)
Table 60. Gerresheimer AG Recent Developments
Table 61. Corium International Basic Information List
Table 62. Corium International Description and Business Overview
Table 63. Corium International Novel Vaccine Delivery Systems Products, Services and Solutions
Table 64. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Corium International (2020-2025)
Table 65. Corium International Recent Developments
Table 66. Inovio Pharmaceuticals Basic Information List
Table 67. Inovio Pharmaceuticals Description and Business Overview
Table 68. Inovio Pharmaceuticals Novel Vaccine Delivery Systems Products, Services and Solutions
Table 69. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Inovio Pharmaceuticals (2020-2025)
Table 70. Inovio Pharmaceuticals Recent Developments
Table 71. Bioject Medical Technologies Basic Information List
Table 72. Bioject Medical Technologies Description and Business Overview
Table 73. Bioject Medical Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
Table 74. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Bioject Medical Technologies (2020-2025)
Table 75. Bioject Medical Technologies Recent Developments
Table 76. PharmaJet Basic Information List
Table 77. PharmaJet Description and Business Overview
Table 78. PharmaJet Novel Vaccine Delivery Systems Products, Services and Solutions
Table 79. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of PharmaJet (2020-2025)
Table 80. PharmaJet Recent Developments
Table 81. Retractable Technologies Basic Information List
Table 82. Retractable Technologies Description and Business Overview
Table 83. Retractable Technologies Novel Vaccine Delivery Systems Products, Services and Solutions
Table 84. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Retractable Technologies (2020-2025)
Table 85. Retractable Technologies Recent Developments
Table 86. Terumo Corporation Basic Information List
Table 87. Terumo Corporation Description and Business Overview
Table 88. Terumo Corporation Novel Vaccine Delivery Systems Products, Services and Solutions
Table 89. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of Terumo Corporation (2020-2025)
Table 90. Terumo Corporation Recent Developments
Table 91. VAXXAS Basic Information List
Table 92. VAXXAS Description and Business Overview
Table 93. VAXXAS Novel Vaccine Delivery Systems Products, Services and Solutions
Table 94. Revenue (US$ Million) in Novel Vaccine Delivery Systems Business of VAXXAS (2020-2025)
Table 95. VAXXAS Recent Developments
Table 96. Key Raw Materials Lists
Table 97. Raw Materials Key Suppliers Lists
Table 98. Novel Vaccine Delivery Systems Downstream Customers
Table 99. Novel Vaccine Delivery Systems Distributors List
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Novel Vaccine Delivery Systems Product Picture
Figure 2. Global Novel Vaccine Delivery Systems Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Novel Vaccine Delivery Systems Sales Value (2020-2031) & (US$ Million)
Figure 4. Novel Vaccine Delivery Systems Report Years Considered
Figure 5. Global Novel Vaccine Delivery Systems Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Novel Vaccine Delivery Systems Revenue in 2024
Figure 7. Novel Vaccine Delivery Systems Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Intradermal Delivery Picture
Figure 9. Intramuscular Delivery Picture
Figure 10. Others Picture
Figure 11. Global Novel Vaccine Delivery Systems Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 12. Global Novel Vaccine Delivery Systems Sales Value Market Share by Type, 2024 & 2031
Figure 13. Product Picture of Hospitals & Clinics
Figure 14. Product Picture of Research Institutes
Figure 15. Product Picture of Others
Figure 16. Global Novel Vaccine Delivery Systems Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 17. Global Novel Vaccine Delivery Systems Sales Value Market Share by Application, 2024 & 2031
Figure 18. North America Novel Vaccine Delivery Systems Sales Value (2020-2031) & (US$ Million)
Figure 19. North America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
Figure 20. Europe Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 21. Europe Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
Figure 22. Asia Pacific Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 23. Asia Pacific Novel Vaccine Delivery Systems Sales Value by Region (%), 2024 VS 2031
Figure 24. South America Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 25. South America Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
Figure 26. Middle East & Africa Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 27. Middle East & Africa Novel Vaccine Delivery Systems Sales Value by Country (%), 2024 VS 2031
Figure 28. Key Countries/Regions Novel Vaccine Delivery Systems Sales Value (%), (2020-2031)
Figure 29. United States Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 30. United States Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 31. United States Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 32. Europe Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 33. Europe Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 34. Europe Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 35. China Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 36. China Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 37. China Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 38. Japan Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 39. Japan Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 40. Japan Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 41. South Korea Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 42. South Korea Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 43. South Korea Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 44. Southeast Asia Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 46. Southeast Asia Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 47. India Novel Vaccine Delivery Systems Sales Value, (2020-2031) & (US$ Million)
Figure 48. India Novel Vaccine Delivery Systems Sales Value by Type (%), 2024 VS 2031
Figure 49. India Novel Vaccine Delivery Systems Sales Value by Application (%), 2024 VS 2031
Figure 50. Novel Vaccine Delivery Systems Industrial Chain
Figure 51. Novel Vaccine Delivery Systems Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
► Intelligent insights to take informed business decisions.
► Qualitative and quantitative analysis of the market.
► Market size and forecasts from 2024 to 2030.
► Opportunities for expansion and in-depth market analysis.
► Segmentation and regional revenue forecasts.
► Analysis of the market share and competitive landscape.
► Strategic recommendations for future growth.
► A comprehensive market research report in PDF or PPT formats.
► Access to our analysts to learn more about the report and get answers to your specific business questions.
► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.